The cannabis industry is one of the fastest growing in the world today. Scientists across the world are studying how this plant which has been marginalized for years can help treat several illnesses. The results of several studies have been decisive in some areas. Cannabis has been shown to have some health benefits for a range of diseases including anxiety, epilepsy, insomnia among others. Now according to a new study in the US, cannabis can provide benefits for people who have multiple sclerosis.

MMJ International Holdings (MMJ-001) is a company that has been conducting studies on how cannabis can treat multiple sclerosis and other neurological diseases. Multiple sclerosis (MS) is described as an unpredictable and often disabling disease that affects the central nervous system and disrupts the flow of information within the brain and also between the brain and the body. There are millions of people living with MS across the world. And scientists have not yet been able to identify the cause of MS.

MMJ-001 has been able to use some of the most active chemical compounds in the treatment of some symptoms of MS such as spasticity or muscle stiffness. This company is looking to bring its cannabis-based MS drug to the United States. MMJ-001 has already gotten the approval of authorities in Canada for its cannabis-based medicine aimed at treating MS and Huntington’s disease.

The Food and Drug Administration (FDA) of the US has given MMJ-001 a ‘Fast Track designation.’ This is required to speed up the clinical testing of their cannabis-based drug meant for the treatment of MS.

MMJ-001 has created a liquid drug from some of the most abundant chemical compounds in the cannabis plant. Cannabidiol (CBD) and Tetrahydrocannabinol (THC) are two of the most active cannabinoids in the cannabis plant. Although they both have different effects on the body, research has shown that these chemical compounds have a plethora of health benefits. CBD does not have the psychoactive effects that have made THC famous. Studies have found that both THC and CBD have neuroprotective properties.

MMJ-001 has made a liquid formulation of CBD and THC which it uses in the treatment of MS. This company is also studying how other cannabinoids in the cannabis plant can help to treat neurological diseases.

The ‘Fast Track designation’ that MMJ-001 has requested from the FDA is specifically for conducting clinical trials on using its cannabis-based drug for treating primary progressive multiple sclerosis (PPMS). The FDA Fast Track designation is for the expedition of treatments for meant for the treatment of severe or life-threatening diseases.

The CEO of MMJ-001 Duane Boise said the studies have provided positive results so far. However, he said, his company is currently working on getting the right doses of CBD and THC for the treatment of PPMS. Boise also said their studies would provide doctors with valuable information concerning cannabis and its effects on health.

The FDA has acknowledged the medicinal benefits that cannabis but insists that more studies need to be conducted. So far, the FDA has approved only one cannabis-based drug meant for the treatment of epilepsy.